Reshape Lifesciences Q1 2024 GAAP EPS $(0.09) Beats $(0.16) Estimate, Sales $1.944M Miss $2.104M Estimate
Portfolio Pulse from Benzinga Newsdesk
Reshape Lifesciences (NASDAQ:RSLS) reported Q1 2024 GAAP EPS of $(0.09), beating the $(0.16) estimate, but sales of $1.944M missed the $2.104M estimate. EPS improved significantly from $(1.56) last year, while sales decreased by 15% from $2.287M.
May 15, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reshape Lifesciences reported better-than-expected Q1 2024 GAAP EPS of $(0.09), beating the $(0.16) estimate. However, sales of $1.944M missed the $2.104M estimate and decreased by 15% from the same period last year.
The better-than-expected EPS is a positive sign, but the miss on sales and the year-over-year decline in revenue may offset the positive sentiment. This mixed result is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100